Mutant KRAS alleles, including G12V/D/C, G13D [151, 152, 229–231], and G12S [232], have also been targeted by the CRISPR/Cas9 system to evaluate their therapeutic potential in PDAC, NSCLC, CRC cells, and animal models. Here, KRAS is linked to non-small cell lung carcinoma.